Results of phase II pharmacokinetic study of levetiracetam for prevention of post‐traumatic epilepsy

► LEV PK was evaluated in a phase 2 study in TBI patients with high risk of PTE. ► LEV 55 mg/kg/d was given ≤ 8 h after TBI for 30 days, with PK done on days 3/30. ► PK was similar to PK in chronic epilepsy patients, across different administration routes and across ages. ► Plasma levels were similar to those seen in positive animal antiepileptogenic studies. ► The study lays the groundwork for LEV evaluation in a phase 3 study of PTE prevention.